SYGNIS announces last patient treated in its AXIS 2 efficacy Study
AX200 has a dual mechanism-of-action in the treatment of acute stroke, stopping neuronal cell death and promoting the regeneration of the damaged CNS tissue, providing a new, first-in-class approach to treating stroke patients.
Dr. Frank Rathgeb, Chief Medical Officer of SYGNIS, commented: “We are pleased to have completed treatment in our clinical phase II efficacy study and are now finalizing the data collection. We expect to report initial findings of the AXIS 2 Study towards the end of 2011“.
Going forward, SYGNIS will review the options for the development and marketing of AX200. Possibilities include continuing development by the company itself or through outlicensing to external parties. In addition, SYGNIS will consider developing AX200 together with a partner.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.